Acelyrin, Inc.
SLRN · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.02 | -0.00 | 0.02 | 0.00 |
| FCF Yield | -97.87% | -34.73% | -16.72% | -8.15% |
| EV / EBITDA | -0.99 | -0.81 | -1.38 | -6.35 |
| Quality | ||||
| ROIC | -68.08% | -64.19% | -22.84% | -46.07% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 1.22 | 0.44 | 0.95 | 0.12 |
| Growth | ||||
| Revenue 3-Year CAGR | – | – | -100.00% | -100.00% |
| Free Cash Flow Growth | -67.68% | -195.84% | -105.21% | 0.00% |
| Safety | ||||
| Net Debt / EBITDA | 0.27 | 0.57 | 4.30 | 2.44 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | -4,217.78 | -133,050.43 | 0.00 | 0.00 |